T. Rowe Price Health Sciences
(PRHSX)
US Markets Close In1 hr 0 min
AdChoices
67.54
+0.83
+1.24%
:

Previous Close

66.71

Net Assets

10.19B

Yield

0.00%

Front load

None

Expenses

0.79%

Category

Health

Morningstar Risk

Above Average

Morningstar Rating ★★★★★
AdChoices
Performance
Returns %
Key statistics
  • Composition
  • Performance
  • Top Holdings
  • Top Rated Funds
  • Fund vs. Category
Quarterly Returns
  • Annual

  • PRHSX

  • Category

    • 2013

    • 51.40%

    • -

    • 2012

    • 31.93%

    • -

    • 2011

    • 11.01%

    • -

    • 2010

    • 16.33%

    • -

    • 2013

    • 2012

    • 2011

      • Q1

      • 15.11%

      • 17.94%

      • 12.45%

      • Q2

      • 3.60%

      • 5.83%

      • 5.32%

      • Q3

      • 16.70%

      • 8.36%

      • -14.31%

      • Q4

      • 8.78%

      • -2.45%

      • 9.38%

      Composition
      Sector Weightings
      Equity Investment Style
      The two dimensions of the Fund Style box measure the average size of companies that have been in the FUND, from the top to bottom, and the average valuation characteristics of the FUND's past stock holdings, from left to right.
      • Name

      • % Portfolio Weight

      • Shares Held

      • Change

        • Gilead Sciences Inc

        • 4.91

        • 5,563,280

        • -2,470,120

        • Alexion Pharmaceuticals Inc

        • 4.71

        • 2,831,800

        • -8,300

        • McKesson Corp

        • 3.44

        • 1,732,900

        • 20,000

        • Biogen Idec Inc

        • 3.42

        • 1,018,500

        • -50,600

        • UnitedHealth Group Inc

        • 3.37

        • 3,865,400

        • -1,025,468

        • Aetna Inc

        • 3.31

        • 3,833,783

        • -35,500

        • Valeant Pharmaceuticals International Inc

        • 3.13

        • 2,332,400

        • 244,800

        • Allergan Inc

        • 2.93

        • 1,622,800

        • 866,500

        • Agilent Technologies Inc

        • 2.69

        • 4,392,330

        • -13,000

        • Danaher Corp

        • 2.50

        • 2,984,800

        • 1,344,800

        • Name

        • Rating

        • YTD Return %

          • Prudential Jennison Health Sciences A LW

          • ★★★★★
          • 15.57

          • VALIC Company I Health Sciences

          • ★★★★★
          • 16.58

          • Prudential Jennison Health Sciences Z

          • ★★★★★
          • 15.85

          • T. Rowe Price Health Sciences

          • ★★★★★
          • 16.85

          • BlackRock Health Sciences Opps Inv C

          • ★★★★
          • 14.54

          • Franklin Biotechnology Discovery A LW

          • ★★★★
          • 17.52

          • Vanguard Health Care Adm

          • ★★★★
          • 16.60

          • Fidelity Advisor® Biotechnology A LW

          • ★★★★
          • 17.10

          • Fidelity Advisor® Health Care A LW

          • ★★★★
          • 18.09

          • Janus Global Life Sciences I

          • ★★★★
          • 17.98

          • Name

          • PRHSX

          • Category

            • Expense Ratio

            • 0.79%

            • 1.45%

            • Net Assets

            • 10.19B

            • 711.24M

            • Dividend Yield

            • 0.54%

            • 0.61

            • Price/Book

            • 3.83

            • 4.82

            • Price/Sales

            • 1.46

            • 3.25

            • Price/Cash Flow

            • 15.76

            • 19.29

            Profile

            Name of Issuer

            T. Rowe Price

            Fund Style

            Open

            Fund Manager

            Taymour Tamaddon

            Investment Style

            Large Growth

            The investment seeks long-term capital appreciation. The fund normally invests at least 80% of its net assets (including any borrowings for investment purposes) in the common stocks of companies engaged in the research, development, production, or distribution of products or services related to health care, medicine, or the life sciences (collectively termed "health sciences"). While it can invest in companies of any size, the majority of fund assets are expected to be invested in large- and mid-capitalization companies. The fund may invest in foreign stocks and options in keeping with the fund's objectives.

            Purchase Information

            Initial Purchase 2,500
            Initial Purchase: IRA 1,000
            Initial Purchase: AIP 2,500
            Front load None
            Back Load None

            Inception

            12/29/1995